Defymed is a company developing innovative implantable medical devices. ExOlin® allows the intraperitoneal delivery of insulin by being coupled to an external insulin pump (start of clinical trials expected by the end of 2020). MailPan® is a device for the macro-encapsulation of insulin-secreting cells. Our goal is to find the best device / cell combination in order to hope for the start of clinical trials in 2022.
Dr Manuel PIRES , Defymed Business Developer :
PreciDIAB is a unique opportunity for Defymed to join a network of opinion leaders in the field of diabetes. Through PreciDIAB, Defymed will participate in workshops and strategic discussions with potential partners.